---
layout: minimal-medicine
title: Belatacept
---

# Belatacept
### Generic Name
Belatacept

### Usage
Belatacept is primarily used to prevent organ rejection in adult patients who have received a kidney transplant.  It's used in combination with other immunosuppressant drugs such as basiliximab (an induction agent), mycophenolate mofetil, and corticosteroids.  While not officially approved for other transplant types, it's sometimes used off-label in lung transplant patients to prevent rejection, though this use requires careful monitoring and carries additional risks.

### Dosage

**Kidney Transplant (Prophylaxis of Rejection):**  Dosage is based on the patient's actual body weight *at the time of transplantation*.  The dose must be evenly divisible by 12.5 mg for accurate preparation.  Crucially, Belatacept should only be used in patients who are Epstein-Barr virus (EBV) seropositive (meaning they have antibodies against EBV).

* **Initial Phase (IV Infusion):** 10 mg/kg on day 1 (transplant day, before implantation) and day 5, followed by 10 mg/kg at the end of weeks 2, 4, 8, and 12.  
* **Maintenance Phase (IV Infusion):** 5 mg/kg every 4 weeks (plus or minus 3 days), starting at the end of week 16.


**Lung Transplant (Off-Label Use - Prophylaxis of Rejection):**

* **Initial Phase (IV Infusion):** 10 mg/kg on days 0 and 4, and again at weeks 2 and 4.
* **Maintenance Phase (Chronic Treatment Only, IV Infusion):** 10 mg/kg every month, starting 4 weeks after the initial phase.

**Important Considerations:**

*  If a patient's body weight changes by more than 10%, the dose should be re-calculated based on the new weight.
*  The IV infusion should be administered over 30 minutes using a low-protein-binding filter.
*  The medication must be used within 24 hours of reconstitution.



### Side Effects

**Common Side Effects (>10%):**

* Headache
* Insomnia
* Peripheral edema
* Hypertension
* Hypotension
* Hypokalemia
* Hyperkalemia
* Hypophosphatemia
* Lipid metabolism disorders
* Hyperglycemia
* Hypocalcemia
* Hypercholesterolemia
* Diarrhea
* Constipation
* Nausea
* Vomiting
* Abdominal pain
* Urinary tract infection
* Dysuria
* Anemia
* Leukopenia
* Infections (various types)
* Arthralgia
* Back pain
* Proteinuria
* Hematuria
* Increased serum creatinine
* Cough
* Upper respiratory tract infection
* Nasopharyngitis
* Dyspnea
* Fever


**Less Common, but Serious Side Effects (1-10% or less):**  These include but are not limited to:  anaphylaxis, progressive multifocal leukoencephalopathy, various types of malignancy (including lymphoproliferative disorders and skin cancer),  and serious infections (including those caused by opportunistic pathogens).

**Note:**  This is not an exhaustive list.  If you experience any adverse effects, contact your healthcare provider immediately.


### How it Works

Belatacept is a selective T-cell costimulation blocker.  T-cells are a type of white blood cell crucial for the immune system's response.  Belatacept works by binding to CD80 and CD86 molecules on antigen-presenting cells.  These molecules are normally involved in activating T-cells. By blocking this interaction, Belatacept reduces the activation of T-cells, preventing them from attacking the transplanted organ and causing rejection.  It also inhibits the production of several cytokines (signaling molecules) involved in inflammation and immune responses.

### Precautions

* **Contraindications:** Belatacept is contraindicated in patients with hypersensitivity to the drug or any of its components, and in EBV-seronegative or EBV-serostatus unknown kidney transplant recipients (due to increased risk of post-transplant lymphoproliferative disorder).
* **Interactions:**  Belatacept may interact with other medications, particularly those metabolized by cytochrome P450 enzymes. Concomitant use with mycophenolate mofetil may increase mycophenolic acid exposure.
* **Warnings:**  Belatacept significantly increases the risk of serious infections, certain types of cancer (especially lymphoproliferative disorders), and post-transplant lymphoproliferative disorder (PTLD), particularly in EBV-seronegative patients.  Careful monitoring is essential.  Use with caution in the elderly.
* **Pregnancy and Breastfeeding:**  Belatacept is a Category C drug in pregnancy.  The potential risks to the fetus should be weighed against the benefits of treatment.  It's unknown whether Belatacept is excreted in breast milk.
* **Other Precautions:**  Avoid live vaccines during treatment.  Regular monitoring of organ function, blood counts, and electrolytes is crucial.


### FAQs

* **Q: How long will I need to take Belatacept?** A: The duration of treatment varies depending on the individual patient and their response to the medication. It typically involves an initial phase followed by a maintenance phase. Your healthcare provider will determine the appropriate duration.

* **Q: What should I do if I miss a dose?** A:  Contact your healthcare provider immediately to determine the best course of action.

* **Q: Can I stop taking Belatacept without consulting my doctor?** A:  No.  Abruptly stopping Belatacept can lead to organ rejection.  Always consult your doctor before making any changes to your medication regimen.

* **Q: How should I store Belatacept?** A: Follow the storage instructions provided by your pharmacist.  

* **Q: What should I do if I experience side effects?** A: Contact your healthcare provider immediately to report any side effects, especially those that are severe or persistent.


**Disclaimer:** This information is intended for educational purposes only and does not constitute medical advice.  Always consult with your healthcare provider for any health concerns or before making any decisions related to your health or treatment.
